Skip Navigation

Cardiovascular Research 2000 45(1):79-81; doi:10.1016/S0008-6363(99)00290-4
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pegram, B. L
Right arrow Articles by Frohlich, E. D
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pegram, B. L
Right arrow Articles by Frohlich, E. D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats

An historical account and some follow-up

Barbara L Pegram, Shozo Ishize and Edward D Frohlich1,*

Alton Ochsner Medical Foundation, New Orleans, LA 70124, USA

* Corresponding author. Tel. +1-504-842-3700; fax: +1-504-842-3258

KEYWORDS Antihypertensive agents; Heart rate (variability); Hemodynamics; Hypertension; Hypertrophy; Ventricular function

The first 10% of the full text of this article appears below.

At the time that our report was written [1], a major change in our thinking about left ventricular hypertrophy (LVH) in hypertension was emerging. The concept that LVH is an independent risk factor for premature cardiovascular morbidity and mortality had become established [2,3]. As a result, the clinical hypothesis was beginning to be tested based upon the experiences with other risk factors. Thus, if the risk of increased morbidity and mortality, associated with elevated systolic and diastolic arterial pressure or elevated serum cholesterol concentration, could be reversed by their respective therapeutic reductions, could not pharmacological reduction of increased LV mass reduce the independent risk associated with LVH? Our . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?